Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers
NCT05483933
Adnexal Diseases, Carcinoma
Little Rock, Arkansas, United States
View Trial DetailsNCT Number: NCT02856841
44 patients were enrolled in this study as they had malignant epithelial ovarian tumor.Pre-operative staging was assessed by CT scan based on FIGO classification and compared to the standard laparotomy surgical staging. Maximal surgical effort for Optimum cytoreduction was achieved and the risk factors for sub-optimal cytoreduction were studied
Looking for future studies?
Notify Me20 year–60 year
Female
Observational
Each patient was subjected to comprehensive medical history taking and careful clinical examination, laboratory investigations (CA-125) and imaging (abdomino-pelvic CT scan). Patients with suspected bowel involvement were subjected for colonoscopy.
Pre-operative Abdomino-pelvic CT scans:
Preoperative CT scans were performed with a high-speed scanner after the oral and intravenous administration of contrast medium. The hard copy images were reviewed by consultant radiologists for assessment of the findings suggestive of malignant adnexal mass which are bilateral lesions, thick septa, enhancing solid components, ascites, and peritoneal deposits .
Pre-operative staging of cancer ovary was assessed by CT scan based on FIGO classification:
Surgical treatment:
All patients underwent standard longitudinal laparotomy, intensive surgical staging and maximal surgical effort for Optimum cytoreduction which was included all of the following (total abdominal hysterectomy, bilateral salpingo-oophorectomy, infracolic-omentectomy, appendectomy, surgical removal of all tumor masses, intestinal resections if required).Achievement of no gross residual disease has been attempted in all cases. Finally, patients were divided into two groups:
Surgical risk factors for optimum cytoreduction:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
FIGO stage II, III, and IV.
Exclusion criteria
Time frame: 1 year after surgery
ability to remove all gross lesions from the tumor intraoperatively and leaving no ovarian lesion seen by naked eye of the expert surgeon
Cairo University
Other
The Preoperative Predictors of Optimal Cytoreductive Surgery in Women With Advanced Epithelial Ovarian Cancer
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05483933
Adnexal Diseases, Carcinoma
Little Rock, Arkansas, United States
View Trial DetailsNCT01309230
Adnexal Diseases, Carcinoma
West Palm Beach, Florida, United States
View Trial DetailsNCT04676334
Adnexal Diseases, Carcinoma
London, Ontario, Canada
View Trial DetailsNCT00408590
Adnexal Diseases, Brenner Tumor
Rochester, Minnesota, United States
View Trial Details